Measles virus neutralizing antibodies in immunoglobulin lots produced from plasma collected in Europe or the United States.
IGIV
Immunoglobulin, intravenous
Immunoglobulin, subcutaneous
Measles vaccination
Neutralization assays
Post-exposure prophylaxis
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
27 05 2019
27 05 2019
Historique:
received:
23
03
2019
revised:
09
04
2019
accepted:
09
04
2019
pubmed:
8
5
2019
medline:
29
9
2020
entrez:
8
5
2019
Statut:
ppublish
Résumé
Vaccination against measles has reduced disease, although measles virus antibody (MVAb) levels are lower after vaccination than natural infection. Immunoglobulin (IG) preparations thus contain decreasing MVAb titers. US IG lot release requires a minimum titer of MVAb, yet equivalent information is not available for other geographies. Using a measles virus neutralization assay, IG fractionated from US or EU plasma is shown to contain similar levels of MVAb always above US regulatory requirements, supportive of equivalent protection against MV infection. Thus, the dosage for post-exposure prophylaxis in the EU could be aligned with the US FDA's treatment recommendations.
Identifiants
pubmed: 31060953
pii: S0264-410X(19)30473-6
doi: 10.1016/j.vaccine.2019.04.022
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulins, Intravenous
0
Measles Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3151-3153Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.